```

[Federal Register Volume 89, Number 222 (Monday, November 18, 2024)]
[Notices]
[Pages 90703-90705]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-26780]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-25-24HQ]

Agency Forms Undergoing Paperwork Reduction Act Review

    In accordance with the Paperwork Reduction Act of 1995, the Centers 
for Disease Control and Prevention (CDC) has submitted the information 
collection request titled ``Division of Diabetes Translation 
Programmatic & Participant User Experience Data Collection (DDTDC)'' to 
the Office of Management and Budget (OMB) for review and approval. CDC 
previously published a ``Proposed Data Collection Submitted for Public 
Comment and Recommendations'' notice on July 26, 2024 to obtain 
comments from the public and affected agencies. CDC received zero 
comments related to the previous notice. This notice serves to allow an 
additional 30 days for public and affected agency comments.
    CDC will accept all comments for this proposed information 
collection project. The Office of Management and Budget is particularly 
interested in comments that:
    (a) Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    (b) Evaluate the accuracy of the agencies estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (c) Enhance the quality, utility, and clarity of the information to 
be collected;
    (d) Minimize the burden of the collection of information on those 
who are to respond, including, through the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology, e.g., permitting 
electronic submission of responses; and
    (e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570. Comments and recommendations for the proposed 
information collection should be sent within 30 days of publication of 
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular 
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct 
written comments and/or suggestions regarding the items contained in 
this notice to the Attention: CDC Desk Officer, Office of Management 
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 
395-5806. Provide written comments within 30 days of notice 
publication.

Proposed Project

    Division of Diabetes Translation Programmatic & Participant User 
Experience Data Collection (DDTDC)--New--National Center for Chronic 
Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease 
Control and Prevention (CDC).

Background and Brief Description

    The Division of Diabetes Translation (DDT) plays a crucial role in 
helping prevent Type 2 diabetes, reducing diabetes complications and 
disability, and reducing diabetes-related disparities across the United 
States. DDT accomplishes this by providing education, training, 
technical assistance (TA), and engaging in communication/marketing 
activities for various key audiences. These customers include national, 
state, and local partners, grantees, providers (e.g., lifestyle 
coaches, diabetes educators, healthcare providers, health/medical and 
community-based organizations), people with prediabetes, diabetes and 
their family, friends, and caregivers, and other consumers of DDT 
products and programs.
    For DDT to be able to efficiently and effectively do this work and 
fulfill its mission, it needs to be able to collect information and 
feedback from intended audiences in a timely manner and with enough 
frequency to ensure DDT can deliver clear, effective, efficient, and 
appropriate customer service. This includes, for instance, collecting 
data on key audiences' needs and on the reach, uptake, use, customer 
experience and satisfaction with DDT's services, products, and related 
programs, including its education, training, TA and communications 
services and products.
    However, in the interest of timely provision of services, DDT often 
forgoes the important step of getting input from its key audiences on 
the clarity, efficiency, effectiveness, and appropriateness of the 
services and resources it develops and provides for them. Skipping this 
information collection step, or doing so with less frequency, avoids 
the delay involved in the standard OMB review process, but increases 
the risk of DDT wasting both time and money developing and providing 
education, training, TA, and communication/marketing that will not 
achieve the intended objectives and will be unclear, irrelevant, or not 
fully meet the needs of DDT's audiences. It can also have other 
unintended consequences, such as jeopardizing the credibility of 
Federal health officials.
    The Division of Diabetes Translation Programmatic & Participant 
User Experience Data Collection (DDTDC) will enable DDT to collect the 
information they require in a timely manner to:
     Provide clear, effective, efficient, appropriate, and 
timely education, communication, training, and technical

[[Page 90704]]

assistance to key audiences and other interested groups, including 
consumer audiences (e.g., people with prediabetes, diabetes, and their 
family, friends, and caregivers), providers (e.g., lifestyle coaches, 
diabetes care and education specialists, healthcare and other 
providers, health/medical and community-based organizations); and 
partners (national, state, and local partners).
     Ensure quality and prevent duplication in the development 
and dissemination of prevention and health information and program 
activities by DDT to consumers, providers, and state and local 
partners.
     Conduct exploratory/formative assessments to inform DDT's 
development of education, communication/marketing, training, and 
programmatic materials, tools, and resources to support and improve the 
prevention and management of diabetes. For example, identifying key 
audiences' knowledge, attitudes, behaviors, motivators, and information 
needs.
     Assess the impact of programs, messages, educational and 
training materials among recipients and determine to what extent they 
meet relevant service-related DDT objectives and goals.
    The following are examples of the areas of focus that the data 
collection activities under this generic information collection 
mechanism may include:
     Reach, uptake, use, customer experience, and satisfaction 
with the CDC-recognized lifestyle change programs for type 2 diabetes 
prevention, as well as related outcomes (e.g., participant retention 
and recruitment rates).
     Satisfaction with CDC-recognized lifestyle change programs 
toolkits, such as the Personal Success Tool and Champion toolkits.
     Reach, uptake, use, customer experience, and satisfaction 
with diabetes education, type 2 prevention, and diabetes management 
innovations (such as the Diabetes Self-Management Education and Support 
services promotion initiative) and related short-term effects on 
knowledge, awareness, practices (such as information seeking), and 
outcomes (such as enrollment of people with diabetes or prediabetes).
     Reach, uptake, satisfaction, customer experience, and 
short-term outcomes of CDC's training and technical assistance 
resources (such as a webinar or online toolkit).
     Needs assessments for customer experience with, 
utilization of, and short-term outcomes of technical assistance and 
trainings for diabetes prevention and management.
     Understandability, ease of use, and appropriateness of 
diabetes education messages, toolkits, programs, and marketing 
materials.
     Exploratory assessments of knowledge, attitudes, 
behaviors, beliefs, barriers, and facilitators to uptake and use of 
lifestyle change programs for diabetes type 2 prevention and diabetes 
management services and related innovations, resources, tools, and 
materials.
    Data collection methods proposed include, but are not limited to 
in-depth individual interviews, cognitive interviews, intercept 
interviews, group-based discussions (including focus groups and dyads/
triads), surveys or questionnaires, knowledge assessments, 
observational assessments, and implementation and utilization data 
reporting. Respondents would include key audiences and stakeholders of 
CDC's work, including representatives of state and local DDT-funded 
organizations; national, state, and local DDT partners (not CDC-
funded); providers of type 2 diabetes prevention and diabetes 
management programs and services, including lifestyle coaches, diabetes 
care and educations specialists, healthcare and other providers; heath/
medical and community-based organizations implementing programs and 
services related to type 2 diabetes prevention and diabetes management; 
people with--and at risk for--diabetes or with prediabetes; family, 
friends, and caregivers of people with--and at risk for--diabetes or 
with prediabetes.
    As the methods for data collection and audiences may vary with each 
request submitted under this proposed generic clearance, for each data 
collection request unique instruments (e.g., surveys, interview guides) 
will be developed to address the specific topics that information will 
be collected on. Questions to be asked may focus, for example, on 
collecting data on the audiences' needs and on the reach, uptake, use, 
customer experience and satisfaction with DDT's services, products, and 
programs. Such information will enable DDT to identify ways to improve 
its services, products, and programs to better meet its audiences' 
needs and achieve its mission of supporting the prevention of diabetes 
and reducing diabetes-related complications and disparities across the 
United States.
    CDC requests a three-year approval for 6,000 burden hours for this 
proposed Generic package. Based on projections, the estimated 
annualized hourly burden anticipated for all data collection methods 
would total 2,000 hours and include eight to ten data collection 
activities over the course of a year. There is no cost to the 
respondents other than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                  Number of          Number
         Type of respondents               Data collection       respondents     responses per    Average burden
                                               methods          across methods     respondent      per response
----------------------------------------------------------------------------------------------------------------
Representatives of state and local     Interviews; surveys or           4,000                1            30/60
 DDT-funded organizations; national,    questionnaires;
 state, and local DDT partners (not     knowledge
 CDC-funded); providers of type 2       assessments;
 diabetes prevention and diabetes       motivation
 management programs and services;      assessments,
 heath/medical and community-based      observational
 organizations implementing programs    assessments;
 and services related to type 2         implementation and
 diabetes prevention and diabetes       utilization data
 management; people with--and at risk   reporting.
 for--diabetes or with prediabetes;
 family, friends, and caregivers of
 people with--and at risk for--
 diabetes or with prediabetes.
----------------------------------------------------------------------------------------------------------------

[[Page 90705]]

Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health 
Ethics and Regulations, Office of Science, Centers for Disease Control 
and Prevention.
[FR Doc. 2024-26780 Filed 11-15-24; 8:45 am]
BILLING CODE 4163-18-P
```